Salvagers of Solubility

High throughput excipient discovery looks set to boost oral bioavailability

August 2017

A collaboration between The Dow Chemical Company and University of Minnesota has yielded a new method allowing the production of excipients that triple the oral bioavailability of drugs, when compared with commercial excipients (1). To further investigate their work, we speak with Theresa Reineke, a professor at the University of Minnesota and Jodi Mecca, a principal research scientist at Dow.

Why is solubility such a problem for drug developers?

The drug discovery process for new chemical entities has shifted to increasingly less soluble APIs, which demand new methods and excipients for delivery. Coupled with the need to understand the mechanism of action in both solid and liquid states makes effective formulation a challenging analytical problem. To build a better foundational understanding of the systems, our work has combined the synthesis of polymers, use of industry standard processing (spray drying), and the development of improved analytical tools. As APIs cover a wide range of chemistries, it is unlikely that a single solution will work in all cases, so an integrated development approach offers the best opportunity for developing API specific solutions.

Related Articles